JournalTOCs

BioCentury Innovations
Number of Followers: 2

Full-text available via subscription

Subscription journal
ISSN (Online) 2377-3030
Published by BioCentury

[1 journal]

May 26 Quick Takes: Carmot raises upsized $150M series E
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 5:22 PM PDT BIOCENTURY FINANCEMAY 26 QUICK TAKES: CARMOT RAISES UPSIZED $150M SERIES EBY Plus: PFS benefit for Imfinzi, Lynparza in endometrial cancer and updates from TScan and Cedars Sinaihttps://www.biocentury.com/article/648104/may-26-quick-takes-carmot-raises-upsized-150m-series-e© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 17:22:46 -070
TIGIT and LAG3 back in the spotlight at ASCO 2023
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 4:52 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTIGIT AND LAG3 BACK IN THE SPOTLIGHT AT ASCO 2023BY Phase I data reignite enthusiasm for checkpoint inhibitors, but will the results reproduce'https://www.biocentury.com/article/648102/tigit-and-lag3-back-in-the-spotlight-at-asco-2023© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 16:52:22 -070
May 26 ASCO Quick Takes: BMS’s Reblozyl headed for SOC in
first-line MDS
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 4:50 PM PDT BIOCENTURY PRODUCT DEVELOPMENTMAY 26 ASCO QUICK TAKES: BMS’S REBLOZYL HEADED FOR SOC IN FIRST-LINE MDSBY Plus: Zentalis’ azenosertib shows early promise in ovarian cancer, and updates from PDS and Elevation https://www.biocentury.com/article/648093/may-26-asco-quick-takes-bms-s-reblozyl-headed-for-soc-in-first-line-mds© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 16:50:25 -070
CHMP seeks to pull Adakveo’s conditional approval; drug has full FDA
approval
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 4:14 PM PDT BIOCENTURY DATA BYTECHMP SEEKS TO PULL ADAKVEO’S CONDITIONAL APPROVAL; DRUG HAS FULL FDA APPROVALBY EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroyahttps://www.biocentury.com/article/648099/chmp-seeks-to-pull-adakveo-s-conditional-approval-drug-has-full-fda-approval© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 16:14:51 -070
Wen leaving Invitae as CFO
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 4:04 PM PDT BIOCENTURY MANAGEMENT TRACKSWEN LEAVING INVITAE AS CFOBY Plus: Fenton succeeds CEO Requadt at Talaris, and an update from Serahttps://www.biocentury.com/article/648109/wen-leaving-invitae-as-cfo© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 16:04:44 -070
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID
vaccine and more
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 3:16 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONEXCISION OF CGG REPEATS IN FRAGILE X; PLUS VLP’S SARNA COVID VACCINE AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648083/excision-of-cgg-repeats-in-fragile-x-plus-vlp-s-sarna-covid-vaccine-and-more© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 15:16:25 -070
U.K. £650M financing package includes major boost for UK Biobank
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 3:14 PM PDT BIOCENTURY POLITICS, POLICY & LAWU.K. £650M FINANCING PACKAGE INCLUDES MAJOR BOOST FOR UK BIOBANKBY Financing policies include streamlined trial approvals, investment vehicles for pensionshttps://www.biocentury.com/article/648097/u-k-650m-financing-package-includes-major-boost-for-uk-biobank© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 15:14:23 -070
Three roads to precision neuropsychiatry, says Manji
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 3:08 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTHREE ROADS TO PRECISION NEUROPSYCHIATRY, SAYS MANJIBY The U.K. launches its Mental Health Mission, naming former J&J exec Husseini Manji as chairhttps://www.biocentury.com/article/648073/three-roads-to-precision-neuropsychiatry-says-manji© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 15:08:29 -070
BIO seeks clarity, transparency on IRA small biotech exemption
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 26, 2023 1:48 PM PDT BIOCENTURY POLITICS, POLICY & LAWBIO SEEKS CLARITY, TRANSPARENCY ON IRA SMALL BIOTECH EXEMPTIONBY Neurocrine and Incyte have said they could qualify for the three-year exemption from price-settinghttps://www.biocentury.com/article/648094/bio-seeks-clarity-transparency-on-ira-small-biotech-exemption© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 26 May 2023 13:48:58 -070
May 25 Quick Takes: VarmX is latest biotech to extend series B
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 5:56 PM PDT BIOCENTURY FINANCEMAY 25 QUICK TAKES: VARMX IS LATEST BIOTECH TO EXTEND SERIES BBY Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and morehttps://www.biocentury.com/article/648069/may-25-quick-takes-varmx-is-latest-biotech-to-extend-series-b© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 17:56:30 -070
Chair Thompson to depart Illumina in partial victory for Icahn
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 5:12 PM PDT BIOCENTURY MANAGEMENT TRACKSCHAIR THOMPSON TO DEPART ILLUMINA IN PARTIAL VICTORY FOR ICAHNBY Activist investor gains one seat on sequencing company's board. Plus: CEO Clark steps down at Destiny and updates from https://www.biocentury.com/article/648079/chair-thompson-to-depart-illumina-in-partial-victory-for-icahn© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 17:12:25 -070
The 20 biggest venture raises year-to-date: genetic medicines
dominate
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 5:07 PM PDT BIOCENTURY DATA BYTETHE 20 BIGGEST VENTURE RAISES YEAR-TO-DATE: GENETIC MEDICINES DOMINATE BY Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines https://www.biocentury.com/article/648065/the-20-biggest-venture-raises-year-to-date-genetic-medicines-dominate© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 17:07:23 -070
Alliance advocates for FDA budget
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 4:14 PM PDT BIOCENTURY POLITICS, POLICY & LAWALLIANCE ADVOCATES FOR FDA BUDGET BY Alliance for a Stronger FDA’s Steven Grossman argues Congress must fund agency as a public goodhttps://www.biocentury.com/article/648084/alliance-advocates-for-fda-budget© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 16:14:25 -070
Default could shutter FDA reviews
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 3:17 PM PDT BIOCENTURY POLITICS, POLICY & LAWDEFAULT COULD SHUTTER FDA REVIEWSBY Even if a debt crisis is averted, agency’s budget is under threathttps://www.biocentury.com/article/648074/default-could-shutter-fda-reviews© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 15:17:02 -070
Turning Point team quietly reforms at Avenzo, raises $196M
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 25, 2023 3:02 PM PDT BIOCENTURY FINANCETURNING POINT TEAM QUIETLY REFORMS AT AVENZO, RAISES $196MBY Led by Athena Countouriotis, cancer start-up hopes to build pipeline by in-licensing ADCs, bispecifics or small moleculeshttps://www.biocentury.com/article/648077/turning-point-team-quietly-reforms-at-avenzo-raises-196m© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 25 May 2023 15:02:39 -070
May 24 Quick Takes: ElevateBio unveils $401M round, base editing deal with
Novo
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 24, 2023 6:15 PM PDT BIOCENTURY DEALSMAY 24 QUICK TAKES: ELEVATEBIO UNVEILS $401M ROUND, BASE EDITING DEAL WITH NOVOBY Plus: Phase III miss for Mirati’s sitravatinib in NSCLC and updates from CMS, Phathom, OnKure, Braeburn, Pyxis-Apexigen, IPIhttps://www.biocentury.com/article/648061/may-24-quick-takes-elevatebio-unveils-401m-round-base-editing-deal-with-novo© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 24 May 2023 18:15:09 -070
Bispecifics improve targeting of liposomal drugs; plus method to interpret
GWAS findings and more
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 24, 2023 5:34 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONBISPECIFICS IMPROVE TARGETING OF LIPOSOMAL DRUGS; PLUS METHOD TO INTERPRET GWAS FINDINGS AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648055/bispecifics-improve-targeting-of-liposomal-drugs-plus-method-to-interpret-gwas-findings-and-more© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 24 May 2023 17:34:46 -070
Alvin Luk named CEO of HuidaGene
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 24, 2023 5:30 PM PDT BIOCENTURY MANAGEMENT TRACKSALVIN LUK NAMED CEO OF HUIDAGENEBY Plus:TScan’s MacBeath now permanent CEO; chair, CMO, seed money for InProTherhttps://www.biocentury.com/article/648067/alvin-luk-named-ceo-of-huidagene© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 24 May 2023 17:30:24 -070
Sarepta’s DMD saga casts more clouds on FDA’s
decision-making
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 24, 2023 5:27 PM PDT BIOCENTURY REGULATIONSAREPTA’S DMD SAGA CASTS MORE CLOUDS ON FDA’S DECISION-MAKING BY A slimmer label for Sarepta’s gene therapy could have big consequenceshttps://www.biocentury.com/article/648062/sarepta-s-dmd-saga-casts-more-clouds-on-fda-s-decision-making© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 24 May 2023 17:27:07 -070
Lupus consortium could be model for joining FDA, NIH, patients and
industry
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 24, 2023 3:28 PM PDT BIOCENTURY PRODUCT DEVELOPMENTLUPUS CONSORTIUM COULD BE MODEL FOR JOINING FDA, NIH, PATIENTS AND INDUSTRYBY ARPA-H seeking ideas for collaboration with FDAhttps://www.biocentury.com/article/648014/lupus-consortium-could-be-model-for-joining-fda-nih-patients-and-industry© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 24 May 2023 15:28:45 -070
May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 5:40 PM PDT BIOCENTURY FINANCEMAY 23 QUICK TAKES: VCS BACK CANCER PLAY LARKSPUR WITH $35.5MBY Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more https://www.biocentury.com/article/648043/may-23-quick-takes-vcs-back-cancer-play-larkspur-with-35-5m© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 17:40:36 -070
The missing links: how to ensure omics data fulfills its promise
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 4:48 PM PDT BIOCENTURY GUEST COMMENTARYTHE MISSING LINKS: HOW TO ENSURE OMICS DATA FULFILLS ITS PROMISEBY Generalizable frameworks for longitudinal studies and interoperable data sharing systems needed to maximize omics impacthttps://www.biocentury.com/article/647907/the-missing-links-how-to-ensure-omics-data-fulfills-its-promise© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 16:48:29 -070
ReNAgade: getting RNA therapies outside the liver
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 4:38 PM PDT BIOCENTURY EMERGING COMPANY PROFILERENAGADE: GETTING RNA THERAPIES OUTSIDE THE LIVERBY Over $300M in series A funding gives the RNA medicines company enough capital to reach the clinichttps://www.biocentury.com/article/648039/renagade-getting-rna-therapies-outside-the-liver© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 16:38:41 -070
Obsidian fills CEO, CDO roles with Iovance vets
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 4:14 PM PDT BIOCENTURY MANAGEMENT TRACKSOBSIDIAN FILLS CEO, CDO ROLES WITH IOVANCE VETSBY Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and morehttps://www.biocentury.com/article/648047/obsidian-fills-ceo-cdo-roles-with-iovance-vets© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 16:14:48 -070
Most-active investors in European biotechs
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 2:36 PM PDT BIOCENTURY DATA BYTEMOST-ACTIVE INVESTORS IN EUROPEAN BIOTECHSBY Novo tops list with 43 investments in European biotechshttps://www.biocentury.com/article/648006/most-active-investors-in-european-biotechs© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 14:36:46 -070
Sizing up VectivBio’s takeout premium among '23 M&A deals
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 23, 2023 2:08 PM PDT BIOCENTURY DEALSSIZING UP VECTIVBIO’S TAKEOUT PREMIUM AMONG '23 M&A DEALSBY Many companies with late-stage assets have commanded triple-digit premiumshttps://www.biocentury.com/article/648021/sizing-up-vectivbio-s-takeout-premium-among-23-m-a-deals© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 23 May 2023 14:08:45 -070
DMD gene therapies, CBER & NIH: a BioCentury podcast
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 22, 2023 5:24 PM PDT BIOCENTURY PRODUCT DEVELOPMENTDMD GENE THERAPIES, CBER & NIH: A BIOCENTURY PODCASTBY The landscape for Duchenne muscular dystrophy gene therapies; plus insights from FDA’s Peter Marks and priorities for Monica Bertagnolli https://www.biocentury.com/article/648026/dmd-gene-therapies-cber-nih-a-biocentury-podcast© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 22 May 2023 17:24:24 -070
Coelho succeeds Lankry as Gamida CFO
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 22, 2023 5:22 PM PDT BIOCENTURY MANAGEMENT TRACKSCOELHO SUCCEEDS LANKRY AS GAMIDA CFOBY Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIHhttps://www.biocentury.com/article/648013/coelho-succeeds-lankry-as-gamida-cfo© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 22 May 2023 17:22:27 -070
May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio
acquisition
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 22, 2023 3:44 PM PDT BIOCENTURY DEALSMAY 22 QUICK TAKES: IRONWOOD BUILDING GI FRANCHISE VIA $1B VECTIVBIO ACQUISITIONBY Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint https://www.biocentury.com/article/648025/may-22-quick-takes-ironwood-building-gi-franchise-via-1b-vectivbio-acquisition© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 22 May 2023 15:44:25 -070
Ning Zhao, WuXi co-founder and philanthropist, passes away
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 22, 2023 3:26 PM PDT BIOCENTURY MANAGEMENT TRACKSNING ZHAO, WUXI CO-FOUNDER AND PHILANTHROPIST, PASSES AWAYBY Scientist, executive helped shape WuXi AppTec, WuXi Biologicshttps://www.biocentury.com/article/648028/ning-zhao-wuxi-co-founder-and-philanthropist-passes-away© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 22 May 2023 15:26:24 -070
Novo’s obesity portfolio gains momentum with oral semaglutide data
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 22, 2023 3:22 PM PDT BIOCENTURY DATA BYTENOVO’S OBESITY PORTFOLIO GAINS MOMENTUM WITH ORAL SEMAGLUTIDE DATABY Oral semaglutide matches Wegovy’s efficacy, but both formulations trail Lilly’s tirzepatidehttps://www.biocentury.com/article/648023/novo-s-obesity-portfolio-gains-momentum-with-oral-semaglutide-data© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 22 May 2023 15:22:48 -070
Targets for severe COVID-19; plus Alzheimer’s resistance case study
and more
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 19, 2023 4:57 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONTARGETS FOR SEVERE COVID-19; PLUS ALZHEIMER’S RESISTANCE CASE STUDY AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648019/targets-for-severe-covid-19-plus-alzheimer-s-resistance-case-study-and-more© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 19 May 2023 16:57:22 -070
Will a gene therapy approval in DMD harm innovation'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 19, 2023 4:29 PM PDT BIOCENTURY PRODUCT DEVELOPMENTWILL A GENE THERAPY APPROVAL IN DMD HARM INNOVATION'BY A deep pipeline of gene therapy candidates follows Sarepta’s SRP-9001, meaning patients may face a tough choicehttps://www.biocentury.com/article/647978/will-a-gene-therapy-approval-in-dmd-harm-innovation© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 19 May 2023 16:29:27 -070
May 19 Quick Takes: AbbVie wins accelerated approval of bispecific for
DLBCL
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 19, 2023 3:51 PM PDT BIOCENTURY REGULATIONMAY 19 QUICK TAKES: ABBVIE WINS ACCELERATED APPROVAL OF BISPECIFIC FOR DLBCLBY Plus: Another setback for Intercept’s NASH candidate, and updates from Krystal, Modernahttps://www.biocentury.com/article/648011/may-19-quick-takes-abbvie-wins-accelerated-approval-of-bispecific-for-dlbcl© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 19 May 2023 15:51:00 -070
Second closing time for series B rounds
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 19, 2023 1:19 PM PDT BIOCENTURY FINANCESECOND CLOSING TIME FOR SERIES B ROUNDSBY Series B extensions represent one third of all series B offerings this yearhttps://www.biocentury.com/article/648002/second-closing-time-for-series-b-rounds© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 19 May 2023 13:19:30 -070
Sandrock’s new Voyage
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 19, 2023 7:46 AM PDT BIOCENTURY PRODUCT DEVELOPMENTSANDROCK’S NEW VOYAGEBY CNS-penetrant capsids could provide platform for Voyager revivalhttps://www.biocentury.com/article/647893/sandrock-s-new-voyage© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 19 May 2023 07:46:36 -070
In vivo CAR T cell advances showcased at ASGCT
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 5:39 PM PDT BIOCENTURY PRODUCT DEVELOPMENTIN VIVO CAR T CELL ADVANCES SHOWCASED AT ASGCTBY Kelonia shows safety in non-human primates, while Umoja shows efficacy in solid tumors in micehttps://www.biocentury.com/article/647974/in-vivo-car-t-cell-advances-showcased-at-asgct© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 17:39:26 -070
Amgen v. Sanofi ruling promotes competition within drug classes
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 5:06 PM PDT BIOCENTURY POLITICS, POLICY & LAWAMGEN V. SANOFI RULING PROMOTES COMPETITION WITHIN DRUG CLASSESBY Supreme Court decision puts an end to antibody genus claims. It could hurt more differentiated innovationhttps://www.biocentury.com/article/647997/amgen-v-sanofi-ruling-promotes-competition-within-drug-classes© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 17:06:30 -070
May 18 Quick Takes: Vaccines panel backs Pfizer RSV vaccine
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 4:25 PM PDT BIOCENTURY REGULATIONMAY 18 QUICK TAKES: VACCINES PANEL BACKS PFIZER RSV VACCINEBY Plus: Pressure mounts on CMS over Alzheimer’s therapies, financing updates for Coherent, Myeloid, Cabaletta, RedCloud, CytoCares, and more https://www.biocentury.com/article/647980/may-18-quick-takes-vaccines-panel-backs-pfizer-rsv-vaccine© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 16:25:20 -070
Teva’s innovative growth strategy, Part Deux
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 2:42 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTEVA’S INNOVATIVE GROWTH STRATEGY, PART DEUXBY Does the pharma have the financial firepower to match its ambition'https://www.biocentury.com/article/648000/teva-s-innovative-growth-strategy-part-deux© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 14:42:22 -070
Klompas steps down as Zymeworks’ COO, president
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 12:20 PM PDT BIOCENTURY MANAGEMENT TRACKSKLOMPAS STEPS DOWN AS ZYMEWORKS’ COO, PRESIDENTBY Plus: Bloom names Colón chair, Replay hires Balakumaran as CMOhttps://www.biocentury.com/article/647996/klompas-steps-down-as-zymeworks-coo-president© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 12:20:21 -070
Regulatory innovations will speed ultra-rare therapies, Marks says
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 18, 2023 5:19 AM PDT BIOCENTURY POLITICS, POLICY & LAWREGULATORY INNOVATIONS WILL SPEED ULTRA-RARE THERAPIES, MARKS SAYSBY On The BioCentury Show, CBER director discusses orphan strategies, pandemic preparedness, management issues https://www.biocentury.com/article/647993/regulatory-innovations-will-speed-ultra-rare-therapies-marks-says© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 18 May 2023 05:19:23 -070
Roche’s Perettie to head cell therapy at Kite
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 17, 2023 5:34 PM PDT BIOCENTURY MANAGEMENT TRACKSROCHE’S PERETTIE TO HEAD CELL THERAPY AT KITEBY Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIGhttps://www.biocentury.com/article/647988/roche-s-perettie-to-head-cell-therapy-at-kite© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 17 May 2023 17:34:22 -070
May 17 Quick Takes: Intercept falls on negative tone of FDA briefing docs
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 17, 2023 4:42 PM PDT BIOCENTURY REGULATIONMAY 17 QUICK TAKES: INTERCEPT FALLS ON NEGATIVE TONE OF FDA BRIEFING DOCSBY Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos https://www.biocentury.com/article/647983/may-17-quick-takes-intercept-falls-on-negative-tone-of-fda-briefing-docs© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 17 May 2023 16:42:26 -070
Acidifying lysosomes to treat NAFLD; Sherlock’s nucleic acid
assay and more
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 17, 2023 3:49 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONACIDIFYING LYSOSOMES TO TREAT NAFLD; SHERLOCK’S NUCLEIC ACID ASSAY AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/647985/acidifying-lysosomes-to-treat-nafld-sherlock-s-nucleic-acid-assay-and-more© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 17 May 2023 15:49:00 -070
Series A financings start to slow
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 17, 2023 3:07 PM PDT BIOCENTURY DATA BYTESERIES A FINANCINGS START TO SLOWBY Fewer biotechs raised series A rounds in the first four months of 2023 than in the same period in the previous four yearshttps://www.biocentury.com/article/647943/series-a-financings-start-to-slow© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 17 May 2023 15:07:40 -070
Nido Bio: treating neurodegeneration with small molecules
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 17, 2023 3:00 PM PDT BIOCENTURY EMERGING COMPANY PROFILENIDO BIO: TREATING NEURODEGENERATION WITH SMALL MOLECULESBY Debuting with $109M, 5AM Ventures-backed company developing small molecule corrector of a genetic neuromuscular diseasehttps://www.biocentury.com/article/647916/nido-bio-treating-neurodegeneration-with-small-molecules© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 17 May 2023 15:00:54 -070
FDA veteran Dunn to join Prothena’s board
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 16, 2023 6:16 PM PDT BIOCENTURY MANAGEMENT TRACKSFDA VETERAN DUNN TO JOIN PROTHENA’S BOARDBY Plus: Lucera named CFO at Editas, and updates from Erasca, Sangamo, AlloVir and morehttps://www.biocentury.com/article/647958/fda-veteran-dunn-to-join-prothena-s-board© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 16 May 2023 18:16:01 -070
Data comp: RSV prophylactics for infants
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 16, 2023 5:46 PM PDT BIOCENTURY DATA BYTEDATA COMP: RSV PROPHYLACTICS FOR INFANTSBY An FDA advisory committee this week will evaluate Pfizer’s Abrysvo vaccine, one of two infant RSV interventions up for FDA approval this yearhttps://www.biocentury.com/article/647967/data-comp-rsv-prophylactics-for-infants© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 16 May 2023 17:46:17 -070
Comparing Phase II NASH data from Viking and Madrigal
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: MAY 16, 2023 5:43 PM PDT BIOCENTURY DATA BYTECOMPARING PHASE II NASH DATA FROM VIKING AND MADRIGALBY Viking’s VK2809 appears to reduce liver fat as well as Madrigal’s resmetirom, which went on to show efficacy in Phase III https://www.biocentury.com/article/647956/comparing-phase-ii-nash-data-from-viking-and-madrigal© 2023 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 16 May 2023 17:43:42 -070